Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$45.56 - $103.81
Previous CloseN/A
Volume113.34K
Average Volume (3M)954.25K
Market Cap
$3.18B
Enterprise Value$4.05B
Total Cash (Recent Filing)$333.73M
Total Debt (Recent Filing)$80.25M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Apr 24, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding54,818,700
10 Day Avg. Volume785,766
30 Day Avg. Volume954,255
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.19
Price to Cash Flow (P/CF)-24.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.55
Enterprise Value/Ebitda-49.41
Forecast
1Y Price Target
$92.44Price Target Upside51.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceAquablation showed significantly improved incontinence and ejaculatory function compared to HoLEP at 3 months.
Financial PerformanceOverall revenue was up 57% year-over-year and beat the Street by 2% as systems revenue beat by 17% and international beat by 27%.
Market GrowthThis is another positive dataset for Procept in a core benign prostatic hyperplasia market only 10% penetrated in the U.S. and even lower globally.
Bears Say
Operating ExpensesPRCT is pulling forward operating expense spend to accelerate enrollment in prostate cancer trials, posing challenges for investors.
Supply Chain DisruptionSaline shortages resulted in the cancellation or delay of up to 2k procedures, impacting 10%-20% of volume.
Valuation ConcernsPRCT currently trades at a significant premium to its high-growth peers, raising concerns about utilization and high expectations given the current valuation.
---
Ownership Overview
9.89% Insiders
37.56% Mutual Funds
22.64% Other Institutional Investors
13.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $45.56 and its highest was $103.81 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $3.18B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Apr 24, 2025 which is in 29 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Feb 25, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.339 by -$0.011.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.49.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 54,818,700 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.339. Following the earnings report the stock price went up 8.611%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
---
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.44 (51.79% Upside)
$92.44 (51.79% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 13.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.75%
12-Months-Change
Fundamentals
Return on Equity
-26.77%
Trailing 12-Months
Asset Growth
31.95%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
---
PRCT Company Deck
---
PRCT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful product launches, and progress in prostate cancer treatment initiatives. However, it also acknowledged challenges such as a significant saline supply disruption affecting procedure volumes and higher-than-expected operating expenses.Read More>---
PRCT Stock 12 Month Forecast
Average Price Target
$92.44
▲(51.79% Upside)
Technical Analysis
Intuitive Surgical
―
Stereotaxis
―
Zimmer Biomet Holdings
―
Globus Medical
―
TransMedics Group
―
Best Analysts Covering PRCT
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+48.37%
reiterated a buy rating 29 days ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +48.37% per trade.
---